Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2005
or
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission file number: 000-23265
SALIX PHARMACEUTICALS, LTD.
(Exact name of Registrant as specified in its charter)
Delaware | 94-3267443 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
8540 Colonnade Center Drive, Suite 501
Raleigh, North Carolina 27615
(Address of principal executive offices, including zip code)
(919) 862-1000
(Registrant’s telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨
Indicate by check mark whether registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). YES x NO ¨
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x
The number of shares of the Registrant’s Common Stock outstanding as of May 5, 2005 was 36,657,721.
Table of Contents
TABLE OF CONTENTS
Page No. | ||||
PART II. | OTHER INFORMATION | |||
Item 6. | Exhibits | 13 | ||
Signatures | 14 |
Explanatory Note
We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 to amend Exhibit 10.50. The amendment is being made to restore provisions of Exhibit 10.50 that we had originally requested be treated confidentially. The restoration of the redacted provisions is being made at the request of the staff of the Securities and Exchange Commission. No other changes have been made to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
Table of Contents
Exhibit Number | Description of Document | Registrant’s | Dated | Exhibit | Filed | |||||
10.50* | Co-promotion Agreement dated March 2, 2005 between Salix Pharmaceuticals, Inc. and Altana Pharma US, Inc. | X | ||||||||
31.1 | Certification by the Chief Executive Officer pursuant to Section 240.13a-14 or section 240.15d-14 of the Securities and Exchange Act of 1934, as amended. | X | ||||||||
31.2 | Certification by the Chief Financial Officer pursuant to Section 240.13a-14 or section 240.15d-14 of the Securities and Exchange Act of 1934, as amended. | X |
* | Certain portions of this agreement have been omitted pursuant to a request for confidential treatment and those portions have been filed separately with the SEC. |
13
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||
Date: August22, 2005 | By: | /s/ Carolyn J. Logan | ||
Carolyn J. Logan | ||||
President and Chief Executive Officer | ||||
Date: August22, 2005 | By: | /s/ Adam C. Derbyshire | ||
Adam C. Derbyshire | ||||
Senior Vice President, Finance & Administration and Chief Financial Officer |
14